The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angiogenesis inhibitors, immune checkpoint inhibitors are experiencing rapid uptake, and the trend toward combination therapies continues to increase. The approvals in 2019 of Keytruda (Merck & Co.) plus Inlyta (Pfizer) and Bavencio (Merck KGaA / Pfizer) plus Inlyta provide alternative options for patients. These therapies will compete with Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis). As uptake of these novel regimens increases, successful drug differentiation strategies will be crucial to ensure physician uptake and preference in this rapidly changing environment.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant renal cell carcinoma patient populations?
  • How has the addition of immune checkpoint inhibitors changed the treatment landscape for renal cell carcinoma? Which populations are most affected?
  • How do physicians differentiate between combination therapies such as Opdivo plus Yervoy, Keytruda plus Inlyta, and Bavencio plus Inlyta? According to U.S. medical oncologists, what is the uptake of these regimens, and which combination is preferred?
  • What factors drive or constrain the prescribing habits of U.S. medical oncologists?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Geographies: United States.

Primary Research: Survey of 100 medical oncologists in the United States.

Key drugs covered: Opdivo, Yervoy, Keytruda, Inlyta, Bavencio, Cabometyx, Sutent, Votrient, Afinitor, Lenvima.

Table of contents

  • Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights Renal Cell Carcinoma US August 2020

Author(s): Priyanka Mehra, B.Tech; Sorcha Cassidy M.Res., Ph.D

Priyanka Mehra is a Business Insights Analyst in the oncology team at Decision Resources Group. She has 5+ years of work experience in pharmaceutical research and analytics, involving management and execution of various strategic analysis projects across multiple oncology indications, secondary and primary research and competitive intelligence. Previously, she worked as an Associate Consultant with Prescient Healthcare Group where she handled Biosimilars projects for global pharmaceutical clients and designed brand and commercial strategy solutions on a variety of therapy areas, including oncology, immunology and inflammatory diseases. Prior to Prescient, she worked as a Senior Analyst with Smart Analyst where she worked on indication prioritization and clinical landscapes for major oncology indications such as NHL, NSCLC and CRC. She has also worked as a Senior Analyst with BioXcel Corporation where she was involved with projects on clinical trials and pipeline analysis, performance benchmarking, scouting and product profiling.

Sorcha Cassidy M.Res., Ph.D., is an Associate Director in the Oncology team at Decision Resources Group.  Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an M.Res and Ph.D in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Related Reports

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populatio...

View Details

Renal Cell Carcinoma - Epidemiology - Emerging Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

View Details